Live Q&A: Castration-Sensitive Prostate Cancer: Navigating the Current Diagnostic and Treatment Landscape
Premiere Date: Thursday, November 18, 2021This activity offers CE credit for:
%>- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, November 18, 2022
Note: Credit Is No Longer Available
Cora N. Sternberg, MD, FACP (Moderator) Clinical Director, Englander Institute for Precision Medicine Professor of Medicine Sandra and Edward Meyer Cancer Center Weill Cornell Medicine New York, NY |
Neal D. Shore, MD, FACS Director, CPI, Carolina Urologic Research Center Chief Surgical Officer, Genesis Care, US Atlantic Urology Clinics Myrtle Beach, SC |
Prostate cancer is the most common cancer in men and the fourth leading cause of cancer death in men. In order to apply current treatment guidelines, it is critical that prostate cancer be accurately staged. Updates to the Gleason scoring system and the introduction of grade groups have improved prognostication and risk stratification. Clinicians need to be able to interpret and act upon pathology reports.
This live Q&A is a follow-up to the first episode of the CME Outfitters podcast series on castration-sensitive prostate cancer (CSPC), which outlined the current state of staging in CSPC and clarified the findings of reports detailing the pathology of prostate cancer specimens.
Click here to view the full activity ahead of this live Q&A.
At the end of this CE activity, participants should be able to:
- Outline the current state of staging in CSPC.
- Interpret the findings of reports detailing the pathology of prostate cancer specimens.
Supported by an educational grant from Astellas and Pfizer, Inc.
Urologists, medical oncologists, PAs, nurse practitioners, nurses, and pharmacists
Information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Sternberg reports that she is a consultant for Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Foundation Medicine, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; National Cancer Institute; Pfizer Inc.; Genentech, Inc./Roche; Sanofi Genzyme; and UroToday.
Dr. Shore reports that he is on the speakers bureau for AstraZeneca; Astellas Pharma US, Inc.; Bayer; Clovis Oncology; Foundation Medicine, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He reports that he is a consultant for AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Bayer; Boston Scientific Corporation; Bristol-Myers Squibb Company; Clovis Oncology; Cold Genesys; Dendreon Pharmaceutical LLC; Exact Imaging; Exact Sciences Corporation; FerGene Inc.; Foundation Medicine, Inc.; GenesisCare; Invitae Corporation; Janssen Pharmaceuticals, Inc.; MDxHealth; Merck & Co., Inc.; Myovant Sciences; Myriad Genetics, Inc.; Nymox Pharmaceuticals Corporation; Pacific Edge; Pfizer Inc.; Phosphorous; PreVie; Propella Therapeutics, Inc.; Sanofi Genzyme; Sesen Bio; Speciality Networks, LLC; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
David Modrak, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PDQ-065-111821-42